7. Antimigraine medicines

7.1. Antimigraine medicines > For treatment of acute attack

Paracetamol (acetaminophen)  

<table>
<thead>
<tr>
<th>Indication</th>
<th>Migraine</th>
<th>ICD11 code: 8A80.Z</th>
</tr>
</thead>
</table>

**INN**  
Paracetamol

**Medicine type**  
Chemical agent

**List type**  
Core

**Additional notes**  
*The presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided*

**Formulations**  
- Oral > Liquid: 125 mg per 5 mL (EMLc); 120 mg per 5 mL (EMLc); 250 mg per 5 mL (EMLc)
- Local > Rectal > Suppository: 250 mg (EMLc)
- Oral > Solid > dispersible tablet: 100 mg (EMLc); 250 mg (EMLc)
- Oral > Solid > tablet: 250 mg; 325 mg; 500 mg

**EML status history**  
- First added in 1987 (TRS 770)
- Changed in 2007 (TRS 950)
- Changed in 2017 (TRS 1006)
- Changed in 2023 (TRS 1049)

**Sex**  
All

**Age**  
Also recommended for children

**Therapeutic alternatives**  
The recommendation is for this specific medicine

**Patent information**  
Patents have expired in most jurisdictions
Read more about patents.

**Wikipedia**  
Paracetamol (acetaminophen)

**DrugBank**  
Paracetamol (Acetaminophen)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:

- The deletion of the 100 mg tablet formulation from the EML and EMLc
- Strengths of paracetamol tablets should be specified rather than given in a range
- The addition of a 250 mg strength suppository formulation to the EMLc
- The addition of paracetamol dispersible tablets (100 mg and 250 mg) to the EMLc
- The addition of 250 mg/5mL strength oral liquid formulation to the EMLc
- The addition of a note stating "the presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided"